Per chi è ancora dentro invito a leggere fra le righe di quanto pubblicato nell'ultimo sec del 18/11/2016
" PARSIPPANY, N.J., November 18 , 2016-- Interpace Diagnostics Group (NASDAQ: IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management, today reported financial and operational results for the third quarter ended September 30, 2016.
Operational and Cash Update :
●
The company has been reducing operational costs and working to restructure obligations incurred related to the sale of the majority of the CSO business in December 2015 as well as obligations related to the acquisition of RedPath. Quarterly installment payments due on the $10.7 million secured note payable to the RedPath shareholders, originally due beginning October 1, 2016,
have been extended to begin on December 31, 2016.
● The company had cash balances of $1.7 million on September 30, 2016 and has negotiated a line of credit of up to $1.2 million and has not drawn down on the facility to date.
Recent Business Updates I nclude:
●
Evidence supporting Interpace Diagnostics’ PanDNA product presented at the American College of Gastroentrerology Annual Meeting by Dr. James Farrell, Director of the Yale Center for Pancreatic Diseases, described when and how PanDNA can help assess long term risk of pancreatic cancer in patients with pancreatic cyst lesions
●
Completed the validation and launch of two new thyroid services designed to assist physicians and clinics that prefer to have the initial Fine Needle Aspirate (FNA) biopsy assessed by an independent third party.
●
Announced New York State approval of ThyGenX ™ for indeterminate thyroid nodules in October enabling us to now market both ThyGenX and ThyraMir in the state, which is known to account for approximately 5% of the 600,000 FNA biopsies in the US annually.
“
During the third quarter, our team continued to perform. Significant new product extensions are being brought to market which, we believe, will keep us on track to meeting our revenue goals. While Q-3 revenues were slightly less than anticipated , we are seeing strong performance in the first month of the fourth quarter ,” said Jack E. Stover, President & CEO. “We are hopeful that further restructurings can be accomplished in a timely manner and accordingly we are continuing to aggressively seek and evaluate strategic alternatives.”
titolo depresso dopo la pubblicazione dei dati al 30/09/2016 ma dopo queste precisazioni di cui sopra e ultimo quarter partito molto bene direi che ci può stare un po' di speculazione al rialzo visto anche lo scarso flottante....vediamo se decidono su eventuale r/s e SE la specula arriva prima o dopo r/s.